To evaluate the effect of Unani medicine Jawarish-e-Shahi in Khafaqan (Palpitation)

Clinical Validation of Unani Pharmacopoeial Formulation Jawarish-e-Shahi in Khafaqan (Palpitation)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016179

Enrollment

300

Registered

2018-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Khafaqan (Palpitation) Health Condition 2: R002- Palpitations

Interventions

Intervention1: Jawarish-e-Shahi: 5 grams orally twice daily for 2 weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 19-60 2. Patients of Palpitation with and without any of the following symptoms/ signs: i. Ghabharat ii. Sweating iii. Nausea iv. Vomiting v. Missed Heart Beat Sensation vi. Fullness in chest vii. Shortness of Breath 3. Normal ECG 4.No Family History

Exclusion criteria

Exclusion criteria: 1. History of any heart diseases 2. History of hepatic, renal disorders, diabetes mellitus, hypertension, anaemia, COPD, etc 3. History of thyroid dysfunction 4. Patients with history of long term use of any other drugs such as anti-epileptic, anti-arrhythmic and anti-psychotic drugs etc. 5. History of Addiction (smoking, alcohol, drugs) 6. Pregnant and lactating women 7. Abnormal ECG 8. Family History

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Khafaqan (Palpitation)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 2 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026